Medication Decision-making in Osteoporosis: Can We Explain Why Patients Do Not Take Their Osteoporosis Medications?

[1] Guggina P(2012)Characteristics associated with anti-osteoporosis medication use data from the Global Longitudinal Study of Osteoporosis in Women (GLOW) USA cohort Bone 51 975-980

[2] Flahive J(2013)Primary nonadherence to bisphosphonates in an integrated healthcare setting Osteoporos Int 24 2509-2517

[3] Hooven FH(2006)Review of adherence to medications for the treatment of osteoporosis Curr Osteop Rep 4 21-27

[4] Reynolds K(2010)Compliance and persistence with osteoporosis medications: a critical review of the literature Rev Endocr Metab Disord 11 275-280

[5] Muntner P(1978)How safe is safe enough? A psychometric study of attitudes towards technological risks and benefits Policy Sci 9 127-152

[6] Cheetham TC(2006)An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US study Curr Med Res Opin 22 949-960

[7] Harrison TN(2013)Patient weighting of osteoporosis medication attributes across racial and ethnic groups: a study of osteoporosis medication preferences using conjoint analysis Osteoporos Int 24 2067-2077

[8] Morisky DE(2001)The extent of patients’ understanding of the risk of treatments Quality Health Care 10 i4-i18

[9] Silverman S(1989)Optimistic biases about personal risks Science 246 1232-1233

[10] Gold DT(2011)Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW) Osteoporos Int 22 27-35

[1] Guggina P(2012)Characteristics associated with anti-osteoporosis medication use data from the Global Longitudinal Study of Osteoporosis in Women (GLOW) USA cohort Bone 51 975-980

[2] Flahive J(2013)Primary nonadherence to bisphosphonates in an integrated healthcare setting Osteoporos Int 24 2509-2517

[3] Hooven FH(2006)Review of adherence to medications for the treatment of osteoporosis Curr Osteop Rep 4 21-27

[4] Reynolds K(2010)Compliance and persistence with osteoporosis medications: a critical review of the literature Rev Endocr Metab Disord 11 275-280

[5] Muntner P(1978)How safe is safe enough? A psychometric study of attitudes towards technological risks and benefits Policy Sci 9 127-152

[6] Cheetham TC(2006)An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US study Curr Med Res Opin 22 949-960

[7] Harrison TN(2013)Patient weighting of osteoporosis medication attributes across racial and ethnic groups: a study of osteoporosis medication preferences using conjoint analysis Osteoporos Int 24 2067-2077

[8] Morisky DE(2001)The extent of patients’ understanding of the risk of treatments Quality Health Care 10 i4-i18

[9] Silverman S(1989)Optimistic biases about personal risks Science 246 1232-1233

[10] Gold DT(2011)Failure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW) Osteoporos Int 22 27-35